How much intravenous contrast is needed in FDG-PET/CT?

Area of Science:

• Radiology
• Nuclear Medicine
• Oncology

Background:

• Intravenous iodinated contrast agents are standard in CT (ceCT) but used cautiously in FDG-PET/CT due to potential artifacts.
• The necessity of contrast agents in oncologic FDG-PET/CT is not fully established for all indications.

Purpose of the Study:

• To clarify the role and indications for intravenous contrast agent use in FDG-PET/CT imaging.
• To optimize imaging protocols and minimize unnecessary radiation exposure in patients undergoing FDG-PET/CT.

Main Methods:

• Review of current literature and clinical practice guidelines regarding contrast agent use in FDG-PET/CT.
• Analysis of specific oncologic indications where contrast-enhanced CT (ceCT) is beneficial versus where it may be omitted.

Main Results:

• Contrast-enhanced CT (ceCT) is crucial in FDG-PET/CT when evaluating vascular structures or tumor invasion into adjacent tissues.
• For certain indications, such as lymphoma, contrast agents may not be necessary for diagnostic accuracy.
• Individualized assessment of contrast necessity is required for each FDG-PET/CT indication.

Conclusions:

• The use of intravenous contrast agents in FDG-PET/CT should be indication-specific.
• Tailoring contrast use can reduce patient radiation burden without compromising diagnostic quality for specific oncologic indications.
• Further research may refine guidelines for contrast administration in FDG-PET/CT.